Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 18/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360598 | 0.90 | PDE10A (0.38) | METFGFR1FGFR3 | |
| SCHEMBL359817 | 0.90 | MET (0.40) | METFGFR1FGFR3 | |
| SCHEMBL255618 | 0.90 | PDE10A (0.38) | METFGFR1FGFR3 | |
| SCHEMBL359940 | 0.90 | MET (0.41) | MET | |
| SCHEMBL367903 | 0.90 | MET (0.40) | METFGFR1FGFR3 | |
| SCHEMBL360828 | 0.90 | MET (0.39) | MET | |
| SCHEMBL173298 | 0.90 | BRD4 (0.38) | METFGFR1FGFR3 | |
| Hydrochloric Acid SCHEMBL174468 | 0.90 | PDE10A (0.37) | METFGFR1FGFR3 | |
| SCHEMBL10283424 | 0.89 | MET (0.37) | METFGFR1FGFR3 | |
| SCHEMBL14915919 | 0.89 | GRK5 (0.38) | METFGFR1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | claimed |
| EP-2611450-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2013-06-20 | — | — | US | disclosed |
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2013-06-20 | — | — | US | disclosed |
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2013-06-20 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| WO-2012030633-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030633-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012009194-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, MET | MET 3/4885FGFR1 58/4885FGFR3 199/4885 |
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MET, ABL1, ERBB2 | MET 1/4885FGFR1 59/4885FGFR3 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.